MetaVia’s Dual OXM Agonist Shows Strong Early Weight-Loss Results

MetaVia’s obesity candidate DA-1726 met all endpoints in a Phase Ib trial, demonstrating robust weight loss and metabolic improvements. DA-1726 is a dual oxyntomodulin (OXM) analogue that activates both the GLP-1 and glucagon receptors, offering a differentiated approach to obesity treatment.

In the eight-week study, patients receiving a non-titrated 48 mg dose achieved an average weight loss of 6.1% after 26 days, rising to 9.1% by day 54. Waist circumference fell by nearly 10 cm, alongside significant improvements in fasting glucose and a 23.7% reduction in liver stiffness. No treatment-related discontinuations were reported, and gastrointestinal side effects were mild to moderate.

MetaVia believes the glucagon component may drive deeper visceral fat loss than GLP-1 therapies alone. The company will now advance DA-1726 into 16-week studies, testing 48 mg and 64 mg titration regimens, as competition intensifies in the rapidly evolving obesity drug market.

07-01-2026